Erythropoietin Attenuates the Memory Deficits in Aging Rats by Rescuing the Oxidative Stress and Inflammation and Promoting BDNF Releasing

Mol Neurobiol. 2016 Oct;53(8):5664-70. doi: 10.1007/s12035-015-9438-1. Epub 2015 Oct 20.

Abstract

Aging is a natural process accompanied with many disorders, including the memory decline. The underlying mechanisms for the age-related memory decline are complicated. Previous work suggested that oxidative stress, inflammatory disturbance, and the neurotropic absence play important roles in the age-related disorders. Thus, to seek a drug to target those abnormalities might be a possible protective approach for aging. Here, we reported that supplements with exogenous erythropoietin (EPO) for 4 weeks could partially rescue the spatial and fear memory impairments in aged rats. The EPO treatment also suppresses the oxidative stress and inflammatory response. Most importantly, EPO supplement restores the mRNA and protein levels of brain-derived neurotrophic factor (BDNF), the critical neurotropic factor for synaptic plasticity and memory. Our study strongly suggests the potential usage of EPO in an anti-aging agent clinically.

Keywords: Aging; BDNF; Cytokines; Memory decline; Oxidative stress.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aging / pathology*
  • Animals
  • Brain / metabolism
  • Brain / pathology
  • Brain / physiopathology
  • Brain-Derived Neurotrophic Factor / metabolism*
  • Erythropoietin / pharmacology
  • Erythropoietin / therapeutic use*
  • Fear / drug effects
  • Inflammation / drug therapy*
  • Inflammation / pathology
  • Male
  • Memory / drug effects
  • Memory Disorders / drug therapy*
  • Memory Disorders / physiopathology
  • Oxidative Stress* / drug effects
  • Rats, Wistar

Substances

  • Brain-Derived Neurotrophic Factor
  • Erythropoietin